Breast MR with special focus on DW-MRI and DCE-MRI

Abstract The use of magnetic resonance imaging (MRI) for the assessment of breast lesions was first described in the 1970s; however, its wide application in clinical routine is relatively recent. The basic principles for diagnosis of a breast lesion rely on the evaluation of signal intensity in T2-weighted sequences, on morphologic assessment and on the evaluation of contrast enhancement behaviour. The quantification of dynamic contrast behaviour by dynamic contrast-enhanced (DCE) MRI and evaluation of the diffusivity of water molecules by means of diffusion-weighted MRI (DW-MRI) have shown promise in the work-up of breast lesions. Therefore, breast MRI has gained a role for all indications that could benefit from its high sensitivity, such as detection of multifocal lesions, detection of contralateral carcinoma and in patients with familial disposition. Breast MRI has been shown to have a role in monitoring of neoadjuvant chemotherapy, for the evaluation of therapeutic results during the course of therapy. Breast MRI can improve the determination of the remaining tumour size at the end of therapy in patients with a minor response. DCE-MRI and DW-MRI have shown potential for improving the early assessment of tumour response to therapy and the assessment of residual tumour after the end of therapy. Breast MRI is important in the postoperative work-up of breast cancers. High sensitivity and specificity have been reported for the diagnosis of recurrence; however, pitfalls such as liponecrosis and changes after radiation therapy have to be carefully considered.

[1]  Ning-Yu An,et al.  Differentiation of clinically benign and malignant breast lesions using diffusion‐weighted imaging , 2002, Journal of magnetic resonance imaging : JMRI.

[2]  C. Kuhl,et al.  Do T2‐weighted pulse sequences help with the differential diagnosis of enhancing lesions in dynamic breast MRI? , 1999, Journal of magnetic resonance imaging : JMRI.

[3]  Brian D Ross,et al.  Predicting and monitoring cancer treatment response with diffusion‐weighted MRI , 2010, Journal of magnetic resonance imaging : JMRI.

[4]  O. Linton,et al.  American College of Radiology , 2018, Definitions.

[5]  W P Dillon,et al.  Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. , 2000, AJNR. American journal of neuroradiology.

[6]  Usha Sinha,et al.  In vivo diffusion‐weighted MRI of the breast: Potential for lesion characterization , 2002, Journal of magnetic resonance imaging : JMRI.

[7]  Hiroshi Honda,et al.  Apparent diffusion coefficients of breast tumors: clinical application. , 2008, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

[8]  I. Zuna,et al.  Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution , 2002, European Radiology.

[9]  Thierry Metens,et al.  Quantitative diffusion imaging in breast cancer: A clinical prospective study , 2006, Journal of magnetic resonance imaging : JMRI.

[10]  E. Grabbe,et al.  Classification of hypervascularized lesions in CE MR imaging of the breast , 2002, European Radiology.

[11]  Shigeru Nawano,et al.  Detecting breast cancer with non-contrast MR imaging: combining diffusion-weighted and STIR imaging. , 2007, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

[12]  G. Tse,et al.  Hamartoma of the breast: a clinicopathological review , 2002, Journal of clinical pathology.

[13]  Shigeru Nawano,et al.  Diffusion-weighted imaging of breast cancer with the sensitivity encoding technique: analysis of the apparent diffusion coefficient value. , 2004, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

[14]  S. Steinberg,et al.  Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. , 2007, Radiology.

[15]  A. Cilotti,et al.  Quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesion , 2007, European Radiology.

[16]  C. Kuhl Concepts for differential diagnosis in breast MR imaging. , 2006, Magnetic resonance imaging clinics of North America.

[17]  Andreas Makris,et al.  Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2008, Clinical Cancer Research.

[18]  Tibor Tot,et al.  Invasive breast cancer: correlation of dynamic MR features with prognostic factors , 2003, European Radiology.

[19]  M D Schnall,et al.  Update of breast MR imaging architectural interpretation model. , 2001, Radiology.

[20]  Peter Gibbs,et al.  Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. , 2006, Magnetic resonance imaging.

[21]  Roberto Orecchia,et al.  Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. , 2010, European journal of cancer.

[22]  Woo Kyung Moon,et al.  Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. , 2010, Radiology.

[23]  R. Matsubayashi,et al.  Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. , 2000, Radiology.

[24]  J. Tominaga,et al.  MR imaging of medullary carcinoma of the breast. , 2009, European journal of radiology.

[25]  K. Flaherty,et al.  Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma , 2008, Cancer biology & therapy.

[26]  S. Gautam,et al.  Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings. , 2010, Radiology.

[27]  C. Kuhl,et al.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? , 1999, Radiology.

[28]  Kevin Camphausen,et al.  Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Hahnfeldt,et al.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.

[30]  W. Kaiser,et al.  Potential MRI interpretation model: differentiation of benign from malignant breast masses. , 2005, AJR. American journal of roentgenology.

[31]  L. Pinali,et al.  Diffusion-weighted magnetic resonance imaging in focal breast lesions: analysis of 78 cases with pathological correlation , 2011, La radiologia medica.

[32]  U. Sharma,et al.  Longitudinal study of the assessment by MRI and diffusion‐weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy , 2009, NMR in biomedicine.

[33]  D. Le Bihan,et al.  Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. , 1988, Radiology.

[34]  M. Miyazaki,et al.  Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography , 2005, European Radiology.

[35]  Yoshito Tsushima,et al.  Magnetic resonance (MR) differential diagnosis of breast tumors using apparent diffusion coefficient (ADC) on 1.5‐T , 2009, Journal of magnetic resonance imaging : JMRI.

[36]  Elizabeth A Morris,et al.  Diagnostic breast MR imaging: current status and future directions. , 2010, Magnetic resonance imaging clinics of North America.

[37]  H. Lehr,et al.  Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. , 2006, Radiology.

[38]  Bong Joo Kang,et al.  The Role of Diffusion-Weighted Imaging and the Apparent Diffusion Coefficient (ADC) Values for Breast Tumors , 2007, Korean journal of radiology.

[39]  A. Padhani,et al.  Assessing changes in tumour vascular function using dynamic contrast‐enhanced magnetic resonance imaging , 2002, NMR in biomedicine.

[40]  Jun Li,et al.  A clinically feasible method to estimate pharmacokinetic parameters in breast cancer. , 2009, Medical physics.

[41]  Fibrocystic change of the breast presenting as a focal lesion mimicking breast cancer in MR imaging , 2008, Journal of magnetic resonance imaging : JMRI.

[42]  F. Sardanelli,et al.  Breast vascular mapping obtained with contrast-enhanced MR imaging: implications for cancer diagnosis, treatment, and risk stratification , 2007, European radiology.

[43]  Davide Caramella,et al.  The role of mean diffusivity (MD) as a predictive index of the response to chemotherapy in locally advanced breast cancer: a preliminary study , 2010, European Radiology.

[44]  Basak Erguvan-Dogan,et al.  BI-RADS-MRI: a primer. , 2006, AJR. American journal of roentgenology.

[45]  P. Choyke,et al.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.